<DOC>
	<DOC>NCT00061542</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of BETOPTIC S and Timolol Gel-forming solution in pediatric patients. Patients will dose with study drug at 8 am and 8 pm daily for twelve weeks. Patients will have vision tested, slit lamp exam, blood pressure and pulse checks at each visit. Patients will have a dilated fundus exam and corneal measurements taken at first and last visit.</brief_summary>
	<brief_title>Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Betaxolol</mesh_term>
	<criteria>INCLUSION: Children 5 years old and younger require treatment for glaucoma or ocular hypertension whose vision is 20/80 or better have a cuptodisc ratio of 0.8 or less EXCLUSION: do not have abnormal fixation IOP greater than 36 mm Hg significant retinal disease penetrating keratoplasty severe ocular pathology optic atrophy eye surgery in the past 30 days cardiovascular abnormalities hypersensitivity to beta blockers</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>